Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Nexosome Oncology
AddedFeb 17, 2024
UpdatedJun 18, 2026
Nexosome Oncology

Nexosome Oncology

Seed

Kentucky-based Nexosome Oncology applies exosome diagnostics in cancer care.

HQ
Lexington, KY, US
Founded
2021
Overview
Compare
Fundraising
Employees
Website

Founded in Lexington, Kentucky, Nexosome Oncology is dedicated to revolutionizing cancer detection through the application of exosome-based diagnostics. Their core mission is to enhance early cancer detection and patient care by leveraging plasma proteomics to identify unique biomarkers. Nexosome Oncology offers highly accurate and reproducible liquid biopsy tests that eliminate the need for invasive tissue biopsies, achieving over 90% accuracy in multiple cancer indications.

Notable figures affiliated with Nexosome Oncology include leading oncologists and researchers in the field of exosome diagnostics. The company has attracted significant investment from healthcare-focused venture capital firms, underscoring its potential impact. Key achievements include identifying approximately 2,000 proteins that provide unique insights into tumor biology and patient responses. Nexosome Oncology's innovative approach has the potential to significantly improve early cancer detection and patient outcomes globally.

Nexosome Oncology - Similar Companies

NX Pharmagen logo

NX Pharmagen

nxpharmagen.com

Exai Bio logo

Exai Bio

exai.bio

Nexo Therapeutics logo

Nexo Therapeutics

nexotx.com

Exovita Biosciences logo

Exovita Biosciences

OncoPrecision logo

OncoPrecision

oncoprecision.bio

OncoSenX logo

OncoSenX

oncosenx.com

Micronoma logo

Micronoma

micronoma.com

Oncocyte logo

Oncocyte

oncocyte.com

Nerx Biosciences logo

Nerx Biosciences

NexEos Diagnostics logo

NexEos Diagnostics

nexeosbio.com

Lucence logo

Lucence

lucence.com

OncXerna Therapeutics logo

OncXerna Therapeutics

oncxerna.com

Oncotect logo

Oncotect

oncotect.co

Salish Bioscience logo

Salish Bioscience

NX Prenatal logo

NX Prenatal

nxprenatal.com

Nexosome Oncology - Quick Facts

Who are Nexosome Oncology's competitors?

Companies similar to Nexosome Oncology include NX Pharmagen, Exai Bio, Nexo Therapeutics and Exovita Biosciences.

When was Nexosome Oncology founded?

Nexosome Oncology was founded in 2021.

Where is Nexosome Oncology's headquarters located?

Nexosome Oncology's headquarters is located in Lexington, KY, US.

When was Nexosome Oncology's last funding round?

Nexosome Oncology's most recent funding round was for $3.7M (USD) in November 2021.

How much has Nexosome Oncology raised to-date?

As of Nov 22, 2021, Nexosome Oncology has raised a total of $3.7M (USD).

How many employees does Nexosome Oncology have?

Nexosome Oncology has 6 employees as of Feb 4, 2024.

Nexosome Oncology - Classification

Ownership
  • Private
Technology
  • Analytics
Geographic Exposure
  • United States
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Cancer Diagnostics
Tags
  • Biotech
  • Data
  • Healthtech
NAICS
  • 620000Health Care and Social Assistance
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
Show 9 more industry codes
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 623000Nursing and Residential Care Facilities
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research